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Platelets have evolved an intricate array of overlapping
mechanisms to respond effectively to vessel damage by
forming a clot to minimize blood loss. Unfortunately,
these same responses may also be triggered by atheroscle-
rotic lesions in diseased arteries. Vessels can become
occluded when platelets form a thrombus at the site of a
ruptured plaque, causing myocardial infarction (MI) or
ischemic stroke, depending on where the thrombus forms
or where a resulting embolus becomes lodged.
Current therapy following MI or ischemic stroke
involves treatment with antiplatelet drugs to reduce the
risk of recurrent events by inhibiting one or more of the
mechanisms that drive the formation of a platelet throm-
bus. However, the overlap between the mechanisms that
drive pathological thrombus formation and those that
facilitate hemostasis means that patients receiving antipla-
telet medication are at higher risk of hemorrhage, includ-
ing intracranial hemorrhage and gastrointestinal bleeding.
The benefits of current antiplatelet therapy outweigh the
risks for patients, but there is still a need for safer anti-
platelet therapies that do not compromise hemostasis to
better serve this patient population, which is large and
growing globally.
In order to develop new antiplatelet drugs, researchers
must consider the similarities and differences between the
pathological process of thrombosis and the physiological
process of hemostasis. Platelets skim over the surfaces of
vascular endothelial cells, scanning for collagen and other
exposed subendothelial matrix proteins that serve as envi-
ronmental cues indicating that vessel damage has
occurred. The initial interaction with exposed collagen
occurs via the plasma protein von Willebrand factor,
which binds to collagen and undergoes conformational
change at high shear rates (present in arteries), enabling
the platelet protein glycoprotein (GP) Iba to bind to it.
Collagen is also recognized directly by the platelet GPVI
receptor and integrin a2b1, which, together, mediate adhe-
sion to collagen and trigger a cascade of intracellular sig-
naling events that ultimately help the aggregate to grow
and become stable. Atherosclerotic plaques are rich in
collagen and provide a strong environmental cue to plate-
lets to adhere and form an aggregate within the lumen of
the vessel. The intracellular signaling processes stimulated
in both scenarios are similar, and result in the platelets
synthesizing thromboxane A2 and secreting ADP, which,
via paracrine and autocrine mechanisms, act as secondary
mediators to recruit platelets to the growing aggregate
and stabilize it. The antiplatelet drugs aspirin and P2Y12
inhibitors such as clopidogrel or ticagrelor target these
positive feedback mechanisms to limit thrombus growth
and prevent vessel occlusion. The success of these drugs
in providing relatively safe platelet inhibition can be
understood in the context of the ‘core’ and ‘shell’ model
of thrombus formation, whereby a core of platelets is
strongly activated by direct contact with collagen, and is
surrounded by an outer shell of weakly activated platelets
stimulated by secondary mediators. In this model, the
core is required for hemostasis, whereas the shell is par-
tially redundant but serves a pathological role in throm-
bosis by causing vessel occlusion. However, both aspirin
and P2Y12 inhibitors are associated with increased rates
of hemorrhage, suggesting that either these drugs are not
sufficiently specific in targeting the shell, or the shell is
also important for hemostasis.
Although the environment of an atherosclerotic plaque
and that of a damaged blood vessel have similarities,
some in vitro studies have identified differences that could
be exploited pharmacologically to provide platelet inhibi-
tion specifically in the context of atherothrombosis while
sparing normal hemostasis. One such difference concerns
the morphologically distinct forms of type I and type III
collagen present in atherosclerotic plaques, which trigger
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thrombus formation via GPVI but not via integrin a2b1
[1]. The traditional model of the interaction of platelets
with collagen involves complementary roles for integrin
a2b1 in mediating adhesion, and GPVI in stimulating
intracellular signaling and full platelet activation. How-
ever, patients who are genetically deficient in platelet
GPVI do not suffer from severe bleeding, suggesting that
the role of GPVI is not as critical for hemostasis as its
role as the primary mediator of collagen-evoked platelet
activation might suggest. The observations that GPVI is
critical for thrombus formation on atherosclerotic plaques
but partially redundant for normal hemostasis prompted
the development of GPVI inhibitors for antiplatelet ther-
apy, which are currently undergoing clinical trials (e.g.
clinicaltrials.gov NCT03312855). Meanwhile, the first clin-
ical Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib,
has been approved for the treatment of chronic lympho-
cytic leukemia and mantle cell lymphoma, and has been
found to cause GPVI-specific platelet dysfunction in
patients. Btk is targeted for the treatment of B-cell lym-
phomas because of its central role in the signaling pathway
that promotes the development of B cells and contributes
towards malignancy. The role of Btk in platelets had
already been established in studies of mice deficient in Btk
and in humans with X-linked gammaglobulinemia who
lack functional Btk; these studies reported that GPVI sig-
naling was at least partially dependent on the presence of
functional Btk. Btk and its family member Tec are known
to couple the GPVI receptor to phospholipase Cc activa-
tion and the release of Ca2+ from intracellular stores into
the cytosol, which is a critical step in collagen-evoked
platelet activation. Like GPVI inhibitors, ibrutinib does
not abolish adhesion to collagen under flow, suggesting
that other receptors and pathways are able to compen-
sate for the loss of Btk activity downstream of GPVI.
However, unlike the absence of severe bleeding in
patients with GPVI or Btk deficiencies, ibrutinib does
increase the risk of major bleeding, suggesting that the
effects of ibrutinib on platelet function cannot be fully
attributable to loss of Btk or GPVI signaling. In support
of this, ibrutinib was found to inhibit platelet function
downstream of other adhesion receptors, including GPIb
and integrin aIIbb3, and to inhibit other platelet kinases,
most importantly Tec and Src family kinases [2,3]. Trials
of the more specific, second-generation Btk inhibitor
acalabrutinib showed no incidents of major bleeding,
and, although the drug was found to inhibit GPVI-
mediated aggregation, it did not inhibit thrombus forma-
tion on native type I collagen [4].
The growing body of evidence surrounding Btk inhibi-
tors and their effects on platelets begs the question of
their potential efficacy in the prevention of atherothrom-
bosis. The recent study by Busygina et al. sought to
address this idea directly by studying the effects of Btk
inhibitors in vitro and ex vivo on the interactions of plate-
lets with atherosclerotic plaque tissue derived from
carotid endarterectomy specimens [5]. Thrombus forma-
tion on homogenized plaque or tissue sections under flow
was abolished by treatment of whole blood with the Btk
inhibitors ibrutinib, acalabrutinib, and ONO/GS-4059 (a
new-generation Btk inhibitor, also referred to as tirabruti-
nib). However, thrombi forming on native type I collagen
were unaffected by acalabrutinib or ONO/GS-4059, and
only partially inhibited by higher concentrations of ibruti-
nib. The finding that ibrutinib abolished thrombus forma-
tion on plaque tissue, but only partially inhibited
thrombus formation on type I collagen, was recapitulated
with blood samples from patients receiving ibrutinib
orally (420 mg daily). The authors argue that the use of
plaque tissue and the use of native type I collagen repre-
sent the pathological process of atherothrombosis and the
physiological process of hemostasis, respectively, and
therefore that Btk inhibitors preferentially target the
pathological processes while sparing hemostasis. If this
model is correct, Btk inhibitors could represent an
entirely new approach to antiplatelet therapy, whereby
the interaction of platelets with the culprit lesion that
triggers vascular events is selectively prevented, while the
ability of platelets to trigger clotting in response to dam-
aged, non-diseased tissue is spared. This view requires
acceptance of the simplified models of hemostasis and
thrombosis used in the study, which cannot fully incorpo-
rate rheological considerations, the contribution of coagu-
lation or extracellular Ca2+ entry, and numerous other
factors that contribute to these processes. However, short
of utilizing a more complex animal model in which
thrombosis is triggered by atherosclerotic plaque rupture
or erosion, it would be difficult to improve on the
approach taken by Busygina et al.
Busygina et al. also theorized that the irreversible mode
of action of ibrutinib could be exploited to achieve inhibi-
tion with low or intermittent dosing, owing to the lack of
protein turnover in the anucleate platelet. Antiplatelet
therapy with the irreversible cyclooxygenase 1 inhibitor
aspirin exploits the lack of platelet protein turnover to
provide effective platelet inhibition at low doses while
minimizing off-target effects. Utilizing this approach, the
authors were able to selectively block thrombus formation
on plaque material by orally dosing healthy volunteers
with 120 mg of ibrutinib every day or every other day,
and achieve similar levels of inhibition as observed in
patients receiving 420 mg daily. The use of low-dose ibru-
tinib for antiplatelet therapy could reduce adverse events
and avoid the off-target inhibition of Src family kinases
that is likely to underpin severe platelet dysfunction and
bleeding caused by higher concentrations of ibrutinib [6].
This strategy could be even more effective with the more
specific Btk inhibitor acalabrutinib, which was only uti-
lized in the in vitro part of the study, but may be associ-
ated with fewer adverse events [4].
Overall, the study provides a compelling basis for
thinking of Btk inhibitors as potential antiplatelet drugs.
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No other kinase inhibitor has been approved for antipla-
telet therapy, and the mode of action of ibrutinib and
other Btk inhibitors in targeting signaling evoked by
adhesion receptors rather than the conventional approach
of preventing interactions of platelet receptors with their
ligands is highly novel. Although existing approved Btk
inhibitors may have potential as antiplatelet drugs, clini-
cal trials to compare their efficacy with that of current
therapies could still be an expensive and risky undertak-
ing for the pharmaceutical industry. The authors suggest
a highly targeted approach for the therapeutic use of Btk
inhibitors as antiplatelet drugs by incorporating them into
prophylactic antithrombotic treatment prior to elective
percutaneous coronary interventions, which can expose
plaque material within the vascular system. Clinical evi-
dence that the interaction between platelets and plaque
material can be pharmacologically targeted would be a
very important development, not only in the context of
Btk inhibitors, but also for antiplatelet drug development
more generally.
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